NIH Intramural Research Program

ATCC Announces Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Award from NIAID

Retrieved on: 
Tuesday, November 28, 2023
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, NIAID, Disease, Acquisition, Vaccine Research Center, VRC, NIH Intramural Research Program, Air tasking order, Bioterrorism, Vaccine, Laboratory, DVM, IDIQ, API, Infection, COVID-19, Biomedical Research, NIH, MBA, Indefinite, Comprehensive, CGMP, Doctor of Philosophy, Active ingredient, Bangladesh Technical Education Board, Public, IRP, Pharmaceutical industry, ATCC

The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).

Key Points: 
  • The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).
  • NIAID’s CARRRP provides the capacity and capability for a broad range of services necessary to support and conduct comprehensive and rapid biomedical research.
  • Under the CARRRP Task Order, ATCC will manage critical biomaterials for the Vaccine Research Center (VRC), one of the three intramural divisions of NIAID’s Intramural Research Program (IRP).
  • “We look forward to working with NIAID and its Intramural Research Program as part of the CARRRP.”

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunoglobulin G, ASN, PMN, UPCR, Investment, Clinical trial, American Society of Nephrology, APRIL, Glomerular filtration rate, Administration, Patient, TACI, Inflammation, Immunoglobulin A, Neonatal Fc receptor, Lupus, Infection, Research program, BAFF, SLE, ALPN, Immunoglobulin M, MD, Development, EGFR, BCMA, Society, NIH Intramural Research Program, Autoimmunity, Proteinuria, AANEM, Pharmaceutical industry, Sewage treatment, Vaccine, Paint, IgA nephropathy, AbbVie, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
  • “Following our data presentation, we executed a follow-on equity offering of $150 million to bolster our balance sheet.
  • Cash Position and Runway: As of September 30, 2023, Alpine’s cash and investments totaled $227.2 million compared to $273.4 million as of December 31, 2022.
  • The respective increases of $0.8 million and $2.3 million were primarily attributable to increases in personnel and legal costs.

BTQ and Hon Hai Research Institute Team Up To Help Pioneer Post-Quantum Cryptography Standards

Retrieved on: 
Wednesday, November 29, 2023
Research, FRA, Electronics, NEO, Algorithm, NIH Intramural Research Program, Collaboration, Foxconn, Research program, Good, BTQ, PQC, Partnership, Molecular reference standards, NIST, Government, Property management, Pharmaceutical industry, Cryptocurrency

BTQ Technologies Corp. announces that its wholly owned subsidiary, BTQ AG, has entered into a Research and Collaboration Agreement with Hon Hai Research Institute.

Key Points: 
  • BTQ Technologies Corp. announces that its wholly owned subsidiary, BTQ AG, has entered into a Research and Collaboration Agreement with Hon Hai Research Institute.
  • In response to the call for PQC standard solicitation by the U.S. National Institute of Standards and Technology (NIST), BTQ and Hon Hai Research Institute's collaborative report was co-published in July 2023, demonstrating their combined expertise and commitment to advancing post-quantum cryptography standards.
  • The collaboration between BTQ and Hon Hai Research Institute began two years ago and the efforts in PQC led to the submission of a milestone report under the Research Program to the US National Institute of Standards and Technology (NIST) on June 1, 2023.
  • The contribution of Hon Hai Research Institute represents the forward-thinking direction in the field of post-quantum cryptography, which is in line with the trend of international academic research.

Folia Health Announces Groundbreaking Flare Tracking Technology to Bridge Research Gaps and Enhance Chronic Condition Management

Retrieved on: 
Thursday, November 9, 2023
Patient, Health care, MPH, NIH Intramural Research Program, Real world evidence, Sickle cell disease, Real world data, Conditional sentence, Health, Quality of life, Research, RWE, Real, Predictive analytics, Algorithm, Nursing, Pharmaceutical industry, Flare

Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.

Key Points: 
  • Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.
  • 3) Bridging Research Gaps: By analyzing Flare data between clinic visits, Folia Health's technology contributes to the wealth of Real World Evidence (RWE), improving our understanding of chronic diseases and refining treatment strategies.
  • Nell Meosky Luo, Chief Executive Officer and Founder at Folia Health, commented, “Our Flare Tracking Technology represents a significant step forward in the understanding of chronic diseases.
  • To learn more about Folia Health's Flare Tracking Technology and its dual impact on chronic disease management and research, please visit https://www.foliahealth.com/research or reach out to [email protected] .

Coalition to Cure Calpain 3 in Partnership with the National Organization for Rare Disorders (NORD®) Launches LGMD2A/Calpainopathy Registry

Retrieved on: 
Thursday, September 21, 2023
Partnership, Drug development, Therapy, NORD, Parent, Community Participation, Policy, Research, National Organization for Rare Disorders, NIH Intramural Research Program, Muscle weakness, C3, Guardians of the Galaxy, Wasting, Patient, Health, Muscular dystrophy, Disease, Medical device, Nursing

Additionally, the study will help identify individuals with Calpainopathy who might be willing to take part in other research studies or clinical trials.

Key Points: 
  • Additionally, the study will help identify individuals with Calpainopathy who might be willing to take part in other research studies or clinical trials.
  • While the original registry served primarily to contact Calpainopathy patients, the new registry will have the capability to collect longitudinal data by having participants periodically update their information.
  • "The LGMD2A/Calpainopathy Registry will provide a complete picture of each patient's experience with this disease," shares Dr. Jennifer Levy, C3 Scientific Director.
  • "This new study has tremendous promise as a strong partnership that engages the patient community and addresses current knowledge gaps for Calpainopathy.

National Organization for Rare Disorders Announces More Than $100,000 in Grant Funding Available for Rare Disease Research

Retrieved on: 
Tuesday, September 19, 2023
LYS, NORD, Syndrome, National Organization for Rare Disorders, NIH Intramural Research Program, Clan, Arteriovenous malformation, AVM, MMIHS, Rare, FDA, NIH, Pharmaceutical industry

DANBURY, Conn., Sept. 19, 2023 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) announced three new grant funding opportunities related to the following rare diseases: Arteriovenous Malformation (AVM), Levy-Yeboa Syndrome (LYS), and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS).  

Key Points: 
  • The National Organization for Rare Disorders (NORD) announces three new research opportunities for AVM, LYS, and MMIHS.
  • NORD's Research Grants Program provides seed-money grants to qualified investigators for scientific and clinical research into diseases for which there are few other sources of funding.
  • With funding by the Maxwell Family, NORD is accepting applications for one grant of up to $40,000 US, for scientific and/or clinical research studies related to Levy-Yeboa syndrome (LYS).
  • To learn more or submit to the 2023 NORD Research Grants Cycle, visit rarediseases.org/advancing-research/request-for-proposals/

Folia Health Reinforces Commitment to Autoimmune and Neurological Conditions: Announcing the Expansion of Multiple Sclerosis, Huntington's Disease, and Myasthenia Gravis User Cohorts

Retrieved on: 
Tuesday, September 5, 2023
HD, Autoimmunity, Prevalence, Registry, Health, Data collection, High reliability organization, Huntington's disease, Research, Myasthenia gravis, Multiple sclerosis, NIH Intramural Research Program, Disorder, HRO, MG, Patient, Collection, MPH, Caregiver, Pharmaceutical industry

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Folia Health, a patient-focused health technology company, proudly announces a user cohort expansion of 3 conditions of great unmet need: Multiple Sclerosis (MS), Huntington's Disease (HD), and Myasthenia Gravis (MG).

Key Points: 
  • BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Folia Health, a patient-focused health technology company, proudly announces a user cohort expansion of 3 conditions of great unmet need: Multiple Sclerosis (MS), Huntington's Disease (HD), and Myasthenia Gravis (MG).
  • We're dedicated to continuing our mission by this dedicated expansion across a series of autoimmune and neurological conditions,” she added.
  • As the prevalence of these disorders continues to rise, Folia Health recognizes the urgency of also accelerating research efforts.
  • "As we continue to build these user cohorts, Folia Health looks forward to opportunities to conduct observational research studies in MS, MG, and HD.

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

Retrieved on: 
Monday, July 24, 2023
Linda, Probability, Doctor of Philosophy, Tufts University Graduate School of Biomedical Sciences, Biogen, Biotechnology, Gene editing, Research, Biomedical sciences, DSM-IV codes, UCB, Patient, NIH Intramural Research Program, Fellow, Drug discovery, IND, Fairfield University, Pharmaceutical industry, Management, Editas Medicine

CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer.

Key Points: 
  • CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer.
  • Dr. Burkly will lead Editas’ drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications.
  • Linda has an outstanding track record of inventing or contributing to the foundations of multiple approved medicines and late-stage clinical candidates.
  • I am eager to lead the incredible team of scientists at Editas to reach this goal together for patients and all of our stakeholders,” said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.

MAPS PBC Announces National Institute on Drug Abuse to Share Data for New Drug Application for MDMA-Assisted Therapy for Treatment of PTSD

Retrieved on: 
Wednesday, June 21, 2023
PK, PBC, Safety, NDA, Pharmacokinetics, Intramural sports, Research, Bangladesh Technical Education Board, Breakthrough therapy, MAPS, Post-traumatic stress disorder, SAN, Chemistry, NIDA, National Institute on Drug Abuse, Safety pharmacology, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mental health, MDMA, Food, PTSD, NIH Intramural Research Program, Pharmaceutical industry

With four decades of independent research looking at its safety, MDMA is one of the most well-studied molecules in clinical development today."

Key Points: 
  • With four decades of independent research looking at its safety, MDMA is one of the most well-studied molecules in clinical development today."
  • MAPS PBC expects to submit the new drug application to the FDA in the second half of 2023.
  • The safety and efficacy of MDMA-assisted therapy have not been established for the treatment of PTSD.
  • This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Aardvark Therapeutics Announces FDA Orphan Drug Designation Granted to ARD-101, a Novel Drug Candidate for Prader-Willi Syndrome

Retrieved on: 
Tuesday, June 20, 2023
Polyphagia, Obesity, Food, International, Prevalence, McCandless, Metabolism, Stanford University, Colorado Children's Chorale, Quality of life, Hope, Neurodevelopmental disorder, Prader–Willi syndrome, Children's Hospital, NIH Intramural Research Program, Trial of the century, Children's Hospital Colorado, CCK, MD, Patient, SAN, Diabetes, Cholecystokinin, Hospital, PWS, FDA, Therapy, Hunger, Caregiver, Gene, DSM-IV codes, Safety, Pharmaceutical industry, Aardvark, Genetics, Endocrinology

The FDA granted Aardvark Orphan Drug Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger.

Key Points: 
  • The FDA granted Aardvark Orphan Drug Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger.
  • SAN DIEGO, June 20, 2023 /PRNewswire/ -- Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company, today reported receipt of an Orphan Drug Designation from the FDA for its lead program, ARD-101, an oral small molecule bitter taste receptor (TAS2R) agonist.
  • Thus far, no drug has been approved by the FDA to treat the hyperphagia associated with PWS.
  • We are so pleased to see the FDA grant Orphan Drug Designation to ARD-101 in recognition of its therapeutic potential based on the promising early clinical findings".